| Identification | Back Directory | [Name]
CAY10726 | [CAS]
1611446-66-2 | [Synonyms]
CAY10726
Hexadecanoic acid, 16-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]- | [Molecular Formula]
C24H36ClF3N2O3 | [MOL File]
1611446-66-2.mol | [Molecular Weight]
493 |
| Chemical Properties | Back Directory | [Boiling point ]
560.9±50.0 °C(Predicted) | [density ]
1.176±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 20 mg/ml; DMF:PBS(pH7.2) (1:2): 0.33 mg/ml; DMSO: 5 mg/ml; Ethanol: 12 mg/ml | [form ]
A crystalline solid | [pka]
4.78±0.10(Predicted) |
| Hazard Information | Back Directory | [Description]
CAY10726 is an arylurea fatty acid.1 It decreases ATP production by 28% in MDA-MB-231 breast cancer cells when used at a concentration of 10 μM. CAY10726 decreases proliferation and initiates apoptosis in MDA-MB-231 cells via depletion of the phospholipid cardiolipin and its precursor phosphatidylglycerol from the mitochondrial membrane. In vivo, CAY10726 (2.5-40 mg/kg) reduces tumor volume and increases tumor cell apoptosis in a mouse MDA-MB-231 breast cancer xenograft model in a dose-dependent manner. | [Uses]
Antitumor agent-159 (Compound 13b) targets the mitochondria and downregulates cardiolipin levels. Antitumor agent-159 inhibits the proliferation of cancer cell MDA-MB-231, arrests the cell cycle at sub-G1 phase, and induces apoptosis in MDA-MB-231. Antitumor agent-159 exhibits antitumor efficacy in MDA-MB-231 xenograft mouse models[1]. | [storage]
Store at -20°C | [References]
1. Rawling, T., Choucair, H., Koolaji, N., et al. A novel arylurea fatty acid that targets the mitochondrion and depletes cardiolipin to promote killing of breast cancer cells J. Med. Chem. 60(20),8661-8666(2017). |
|
|